Use of Ozone-Depleting Substances; Removal of Essential-Use Designation (Flunisolide, etc.); Correction

Document Headings Document headings vary by document type but may contain the following: the agency or agencies that issued and signed a document the number of the CFR title and the number of each part the document amends, proposes to amend, or is directly related to the agency docket number / agency internal file number the RIN which identifies each regulatory action listed in the Unified Agenda of Federal Regulatory and Deregulatory Actions See the Document Drafting Handbook for more details. Department of Health and Human Services Food and Drug Administration 21 CFR Part 2 [Docket No. FDA-2006-N-0304] (formerly Docket No. 2006N-0262) RIN 0910-AF93 AGENCY: Food and Drug Administration, HHS. ACTION: Final rule; correction. SUMMARY: The Food and Drug Administration (FDA) is correcting a final rule that appeared in the Federal Register of April 14, 2010 ( 75 FR 19213 ). The document amended FDA's regulation on the use of ozone-depleting substances (ODSs) in self-pressurized containers to remove the essential-use designations for flunisolide, triamcinolone, metaproterenol, pirbuterol, albuterol and ipratropium in combination, cromolyn, and nedocromil used in oral pressurized metered-dose inhalers (MDIs). The document was published with an inadvertent error. This document corrects that error. FOR FURTHER INFORMATION CONTACT: Diane Sullivan, Office of Policy, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, rm. 3210, Silver Spring, MD 20993, 301-796-9171. SUPPLEMENTARY INFORMATION: In FR Doc. 2010-8467 , appearing on page 19213, in the Federal Register of Wednesday, April 14, 2010, the following correction is made: 1. On page 19213, in the third column, the heading “RIN 0910-AF92” is corrected to read “RIN 0910-AF93”. Dated: September 13, 2010. David Dorsey, Acting Deputy Commissioner for Policy, Planning and Budget. [ FR Doc. 2010-23195 Filed 9-16-10; 8:45 am] BILLING CODE 4160-01-S